ROX Medical, a San Clemente, Calif.-based early phase medical device company that is pioneering an innovative treatment for Chronic Obstructive Pulmonary Disease (COPD), has closed a $6m financing round.
Backers include existing investors Domain Associates and Versant Ventures.
The company intends to use the capital to initiate an international trial of the ROX FLOW procedure for the treatment of resistant hypertension (high blood pressure).
Led by CEO Rodney Brenneman, ROX Medical has developed a short, minimally invasive, catheter-based procedure whereby Interventional Cardiologists, Radiologists or Endovascular Specialists place a stent-like connection between the artery and vein in the upper leg. It is intended to reduce peripheral vascular resistance, thereby holding the promise of a meaningful long-term reduction in hypertension.
The ROX FLOW procedure for hypertension is not approved for use in the U.S.